← CORCEPT THERAPEUTICS INC

Annual Trend FY 2016 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
Cash flows from operating activities:
Adjustments to reconcile net income to net cash provided by operating activities:
Net Income (Loss) Attributable to Parent $8.1m $129.1m $75.4m $94.2m $106.0m $112.5m $101.4m $106.1m $141.2m $99.7m
Net Income (Loss) Available to Common Stockholders, Basic $8.1m $129.1m $75.4m $94.2m $106.0m $112.5m $101.3m $105.5m $139.7m $98.2m
Depreciation, Depletion and Amortization $87k $106k $236k $703k $525k $1.1m $782k $577k $795k $1.1m
Amortization of Debt Issuance Costs $21k $14k $0 $0 — — — — — —
Amortization of Intangible Assets — — — — — — — $465k — —
Deferred Income Tax Expense (Benefit) — ($76.7m) $14.1m $16.9m $14.1m $4.3m ($33.9m) ($29.5m) ($40.2m) ($37.5m)
Share-based Payment Arrangement, Noncash Expense $7.1m $13.4m $23.7m $29.3m $33.5m $42.9m $42.4m $48.9m $61.4m $84.5m
Payment, Tax Withholding, Share-based Payment Arrangement — — — $6.1m $1.1m $22.8m $21.7m $9.1m $22.3m $72.9m
Share-based Payment Arrangement, Expense $7.1m $13.4m — — — — — — — —
Share-based Payment Arrangement, Expensed and Capitalized, Amount — — $23.8m $29.4m $33.8m $43.2m $42.7m $49.1m $61.7m $85.0m
Income Tax Expense (Benefit) $0 ($76.3m) $16.7m $22.5m $25.6m $12.5m $14.8m $18.4m $20.3m ($33.2m)
Operating Lease, Expense — — — $1.5m $1.9m $2.1m $2.3m $2.4m — —
Changes in operating assets and liabilities:
Additional Financial Items
Increase (Decrease) in Accounts Receivable $3.6m $5.4m $2.3m $2.3m $6.3m $1.4m $3.4m $10.1m $12.9m $5.8m
Increase (Decrease) in Inventories $682k $2.3m $7.8m $1.0m $3.5m ($3.4m) ($1.2m) ($1.3m) ($305k) $7.5m
Increase (Decrease) in Accounts Payable $965k $6.3m ($389k) ($735k) $3.2m ($3.6m) $4.8m $5.8m ($2.2m) $25.1m
Proceeds from Stock Options Exercised $7.7m $7.2m — — — — — — — $15.9m
Accretion Expense $1.9m $456k $0 — — — — — — —
Marketable Securities, Unrealized Gain (Loss) — ($75k) $5k — — — — — — —
Nonoperating Income (Expense) — — — — — — — $17.3m $24.5m $21.7m
Net Cash Provided by (Used in) Operating Activities $18.4m $60.9m $115.7m $136.1m $152.0m $167.9m $120.3m $127.0m $198.1m $142.0m
Cash flows from investing activities:
Payments to Acquire Property, Plant, and Equipment $194k $419k $298k $1.1m $1.2m $469k $413k $139k $2.2m $211k
Net Cash Provided by (Used in) Investing Activities ($194k) ($73.5m) ($90.8m) ($117.8m) ($119.3m) $136.1m ($114.3m) $90.9m ($177.6m) $69.8m
Cash flows from financing activities:
Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale $0 $29.9m $142.7m $182.3m $302.1m $398.9m $241.2m $419.8m $412.9m $389.6m
Repayments of Long-term Debt $14.8m $15.1m $0 $0 — — — — — —
Payments for Repurchase of Common Stock $0 $0 $23.7m $31.0m $9.9m $296.0m $0 $145.4m $15.7m $172.9m
Net Cash Provided by (Used in) Financing Activities ($7.1m) ($8.0m) ($14.3m) ($28.6m) $12.2m ($302.6m) ($17.3m) ($148.7m) ($28.3m) ($220.4m)
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents — — — — — — — $358k ($228k) $1.4m
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect — — — — $44.9m $1.4m ($11.3m) $69.2m ($7.9m) ($7.2m)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents — — — — $76.2m $77.6m $66.3m $135.6m $127.7m $120.5m
Supplemental disclosure of cash flow information:
Income Taxes Paid, Net $40k $377k $1.4m $6.7m $10.9m $9.1m $39.7m $47.6m $60.3m $13.0m

Data sourced from SEC EDGAR 10-K filings via EdgarTools. Amounts are shown in USD as reported in each fiscal year filing.